301 related articles for article (PubMed ID: 30458661)
1. Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Hjorth CF; Nielsen AS; Sørensen HT; Lash TL; Damkier P; Hamilton-Dutoit S; Cronin-Fenton D
Acta Oncol; 2019 Feb; 58(2):168-174. PubMed ID: 30458661
[TBL] [Abstract][Full Text] [Related]
2. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
3. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study.
Collin LJ; Maliniak ML; Cronin-Fenton DP; Ahern TP; Christensen KB; Ulrichsen SP; Damkier P; Hamilton-Dutoit S; Yacoub R; Christiansen PM; Sørensen HT; Lash TL
Breast Cancer Res; 2021 Nov; 23(1):103. PubMed ID: 34736510
[TBL] [Abstract][Full Text] [Related]
5. Expression of survivin does not appear to influence breast cancer recurrence risk.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christensen KB; Damkier P; Hamilton-Dutoit S; Kjaersgaard A; Lauridsen KL; Yacoub R; Christiansen P; Sørensen HT; Lash TL
Acta Oncol; 2019 Feb; 58(2):154-161. PubMed ID: 30351173
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with concordant estrogen receptor expression at diagnosis and centralized re-assay in a Danish population-based breast cancer study.
Cronin-Fenton DP; Hellberg Y; Lauridsen KL; Ahern TP; Garne JP; Rosenberg C; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
Acta Oncol; 2012 Feb; 51(2):254-61. PubMed ID: 22129357
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
Klebaner D; Hamilton-Dutoit S; Ahern T; Crawford A; Jakobsen T; Cronin-Fenton DP; Damkier P; Janssen E; Kjaersgaard A; Ording AG; Søiland H; Sørensen HT; Lash TL; Hellberg Y
PLoS One; 2017; 12(3):e0171453. PubMed ID: 28301514
[TBL] [Abstract][Full Text] [Related]
9. Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark.
Collin LJ; Cronin-Fenton DP; Ahern TP; Christiansen PM; Damkier P; Ejlertsen B; Hamilton-Dutoit S; Kjærsgaard A; Silliman RA; Sørensen HT; Lash TL
BMJ Open; 2018 Aug; 8(7):e021805. PubMed ID: 30068618
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.
Li CI; Daling JR; Porter PL; Tang MT; Malone KE
Cancer Res; 2009 Sep; 69(17):6865-70. PubMed ID: 19706753
[TBL] [Abstract][Full Text] [Related]
11. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
14. Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model.
De Oliveira Andrade F; Yu W; Zhang X; Carney E; Hu R; Clarke R; FitzGerald K; Hilakivi-Clarke L
Endocr Relat Cancer; 2019 Mar; 26(3):339-353. PubMed ID: 30640711
[TBL] [Abstract][Full Text] [Related]
15. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
16. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
18. Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.
Ahern TP; Christensen M; Cronin-Fenton DP; Lunetta KL; Søiland H; Gjerde J; Garne JP; Rosenberg CL; Silliman RA; Sørensen HT; Lash TL; Hamilton-Dutoit S
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1937-43. PubMed ID: 21750172
[TBL] [Abstract][Full Text] [Related]
19. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
20. Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial).
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Fresney M; Kerbrat P; Veyret C; de Lafontan B; Janvier M; Macé-Lesech J
Ann Oncol; 2000 May; 11(5):515-9. PubMed ID: 10907942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
